Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

First Posted Date
2009-10-02
Last Posted Date
2012-11-27
Lead Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Target Recruit Count
276
Registration Number
NCT00988780
Locations
🇺🇸

NIH/NIAD, Bethesda, Maryland, United States

🇲🇽

Hospital General de León, Leon, Guanajuato, Mexico

🇺🇸

HIV-1 Immunopathogenesis Laboratory. The Wistar Institute, Philadelphia, Pennsylvania, United States

and more 7 locations

The Maraviroc Central Nervous System (CNS) Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-09-23
Last Posted Date
2019-11-04
Lead Sponsor
Imperial College London
Target Recruit Count
13
Registration Number
NCT00982878
Locations
🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

The St. Marys and The Mater Switch Study

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2009-09-22
Last Posted Date
2019-09-12
Lead Sponsor
Imperial College London
Target Recruit Count
18
Registration Number
NCT00981773
Locations
🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

🇮🇪

Cork University Hospital, Cork, Ireland

🇮🇪

Mater Misericordiae University Hospital, Dublin, Ireland

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-08-26
Last Posted Date
2013-01-24
Lead Sponsor
Germans Trias i Pujol Hospital
Target Recruit Count
30
Registration Number
NCT00966329
Locations
🇪🇸

Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

🇪🇸

Lluita contra la Sida Foundation, HIV Unit, Badalona, Barcelona, Spain

🇪🇸

Lluita contra la Sida Foundation, HIV Unit, Irsi Caixa Foundation, Badalona, Barcelona, Spain

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Phase 2
Completed
Conditions
First Posted Date
2009-07-23
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
60
Registration Number
NCT00944541
Locations
🇫🇷

French National Agency for Research on AIDS and Viral Hepatits, Paris, France

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-06-22
Last Posted Date
2020-08-19
Lead Sponsor
University of California, San Diego
Target Recruit Count
32
Registration Number
NCT00925756
Locations
🇺🇸

Harbor-UCLA, Torrance, California, United States

🇺🇸

University California San Diego, San Diego, California, United States

🇺🇸

University Southern California, Los Angeles, California, United States

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-04-21
Last Posted Date
2013-04-30
Lead Sponsor
ASST Fatebenefratelli Sacco
Target Recruit Count
100
Registration Number
NCT00884858
Locations
🇮🇹

Servizio Regionale di Immunologia Clinica e Tipizzazione Tissutale, Azienda Ospedaliero-Universitaria, Torrette di Ancona, AN, Italy

🇮🇹

Clinica di Malattie Infettive, Policlinico, Universita' degli Studi, Bari, BA, Italy

🇮🇹

Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Spedali civili, Brescia, BS, Italy

and more 17 locations

Maraviroc Immune Recovery Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-04-03
Last Posted Date
2013-09-10
Lead Sponsor
S.F.L. van Lelyveld
Target Recruit Count
85
Registration Number
NCT00875368
Locations
🇳🇱

Erasmus MC, Rotterdam, Netherlands

🇳🇱

Sint Elisabeth Ziekenhuis, Tilburg, Netherlands

🇳🇱

Academisch Medisch Centrum (AMC), Amsterdam, Netherlands

and more 7 locations

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-03-02
Last Posted Date
2013-01-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
18
Registration Number
NCT00853840
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Completed
Conditions
Interventions
First Posted Date
2009-02-25
Last Posted Date
2012-11-07
Lead Sponsor
ViiV Healthcare
Target Recruit Count
79
Registration Number
NCT00850395
© Copyright 2024. All Rights Reserved by MedPath